Clinical Trial Update: DCHA as Postremission Therapy for AML With t(8;21) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describing Phase 1 and Phase 2 studies of DCHA as postremission therapy for acute myeloid leukemia with t(8;21).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with

Drugs mentioned

• DCHA

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Chemotherapy | Phase 1, Phase 2 | Status: UNKNOWN